Quote:

---

It looks like Leronlimab will compliment Bevacizumab based on this study

---

It will be interesting to see although I have my doubts about it complimenting leronlimab. Bevacizumab blocks VEGF which is responsible for angiogenesis (growth of new blood vessels) in tumors and helps induce a shift to an M2 macrophage state (helps protect tumor cells from being killed). VEGF production is highly driven by CCL5 (RANTES) and in a feedback loop VEGF can increase CCL5. Lo and behold leronlimab blocks CCL5 from binding to the CCR5 receptor downregulating VEGF and breaking the feedback loop. Which is one of the ways leronlimab has been shown to greatly reduce angiogenesis and switch to an M1 macrophage state (tumor fighting). Bevacizumab only affects VEGF, leronlimab does that and so much more.


Bevacizumab has a slew of side effects, leronlimab doesn't because leronlimab greatly reduces VEGF but doesn't block it from interacting with other CCR receptors so the essential functions of VEGF are still available. You don't want a massive shutdown of any essential protein like a lot of drugs do. It's all about balance.

Unfortunately we're stuck with bevacizumab and it's side effects because it's been approved for colorectal cancer and the FDA would insist on having a drug that's known to be effective to pair with even if your drug does the same thing. Which is reasonable because if your drug does nothing at least the patients will get some treatment. My mind is spinning in circles trying to figure out how to get out of the quandary of combo trials.